What tirzepatide does to your hormone balance

What the incretin system actually does, and why it matters for weight

Most people have heard that GLP-1 is involved in appetite suppression, but the mechanism is worth understanding properly rather than reducing it to "a hunger hormone." GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones, meaning they are released from cells in the gut wall in the minutes after you eat. Their job is to signal to the pancreas to release insulin in proportion to the meal, and to signal to the brain (via the hypothalamus and brainstem) that food has arrived and fullness is approaching.

In people living with obesity, this system frequently under-performs. The gut still releases these hormones, but the receptors respond less efficiently, so the satiety signal is weaker and takes longer to arrive. That is not a failure of willpower; it is a measurable change in receptor sensitivity documented in peer-reviewed literature. Tirzepatide works by binding directly to both the GIP receptor and the GLP-1 receptor, producing a stronger and more sustained signal than the body's own hormones typically manage. The result, as the NHS medicines page for tirzepatide notes, is reduced appetite, a slower rate of gastric emptying and, ultimately, reduced calorie intake. The hormone balance angle here is not about oestrogen or testosterone, it is about the gut-to-brain signalling axis that governs hunger.

For readers curious about how tirzepatide compares to other hormonal pathways, whether Mounjaro qualifies as a hormone treatment is a question our prescribers hear regularly, and there is a fuller answer on that page.

How dual GIP and GLP-1 activation differs from a single-pathway approach

Before tirzepatide, every GLP-1 medicine on the market (including semaglutide (Wegovy)) worked through a single receptor. Adding GIP activation is not simply doubling up on the same signal. The two receptors sit in different parts of the body and trigger overlapping but distinct responses. GLP-1 receptor activation is primarily responsible for slowing gastric emptying and suppressing glucagon (the hormone that raises blood sugar between meals). GIP receptor activation appears to add a complementary effect on fat tissue metabolism and may improve the sensitivity of other receptors to GLP-1, which means the combined signal lands harder than either would alone.

The clinical evidence reflects this. In SURMOUNT-1 (the phase 3 trial published in the New England Journal of Medicine) average weight loss at the 15mg maintenance dose reached approximately 20–21% of body weight over 72 weeks. The head-to-head SURMOUNT-5 trial, also published in the NEJM in 2025, directly compared tirzepatide against semaglutide 2.4mg and found greater average weight loss with tirzepatide. NICE reviewed this evidence before recommending tirzepatide in Technology Appraisal 1026, published December 2024. The dual-receptor mechanism is central to why that gap exists.

If you want more detail on tirzepatide's broader hormonal effects, there is a dedicated page covering how Mounjaro interacts with the body's hormonal systems in more depth.

Insulin, glucagon and what this means beyond appetite

A common misconception is that tirzepatide is purely an appetite suppressant, a kind of pharmaceutical willpower. The hormonal picture is more layered than that. Because GLP-1 receptor activation stimulates insulin secretion in a glucose-dependent way (meaning it only triggers insulin release when blood sugar is already elevated), tirzepatide also helps stabilise post-meal blood glucose. At the same time, it suppresses glucagon, which normally signals the liver to release stored glucose between meals. That combination is why the medicine holds a licence for type 2 diabetes as well as weight management.

For people without diabetes, these effects still matter. Improved insulin sensitivity as weight falls tends to reduce the baseline hormonal disruption that often accompanies obesity, including the way excess adipose tissue produces pro-inflammatory signals and alters sex-hormone metabolism. Tirzepatide does not directly target oestrogen, progesterone or testosterone, but secondary changes in those pathways are plausible as body composition shifts. Readers asking specifically about tirzepatide's effects on female hormones will find a more focused discussion there.

The treatment is available as a once-weekly subcutaneous injection (Mounjaro KwikPen) in six UK strengths from 2.5mg to 15mg, titrated by the prescriber. For a wider overview of how Mounjaro is used in practice, the Mounjaro treatment page covers eligibility, the prescribing process and what to expect. On questions of cost, the context behind recent UK pricing changes is set out separately.

What tirzepatide does not do (and why that matters for realistic expectations

The hormonal effects of tirzepatide are real and well-documented, but they work alongside a reduced-calorie diet and increased physical activity) not instead of them. The medicine shifts the hormonal environment in ways that make eating less feel considerably more manageable; it does not override the need for lifestyle change or make weight management effortless. Trials consistently enrolled participants who were following structured dietary guidance alongside the injection, and the results reflect that combined approach.

Tirzepatide is also a prescription-only medicine, which means a prescriber must assess whether it is appropriate for you specifically. Certain conditions (including a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and some other gastrointestinal conditions) require careful prescriber review. It is not recommended during pregnancy, breastfeeding or when trying to conceive, and it is not licensed for under-18s. Side effects are mostly gastrointestinal (nausea, constipation, indigestion) and tend to settle as the body adjusts to each dose level.

For people who want to understand more about the full range of ways Mounjaro may affect hormones, that page brings together the broader evidence. And if you have questions our pages have not covered, our FAQs are a useful first stop before speaking to the team. When you are ready, speak to our prescribers through a free consultation, a named, GPhC-registered clinician reviews your answers the same day.